aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $49.69 million. The enterprise value is -$3.56 million.
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 98.05 million shares outstanding. The number of shares has increased by 20.81% in one year.
| Current Share Class | 98.05M |
| Shares Outstanding | 98.05M |
| Shares Change (YoY) | +20.81% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 2.49% |
| Owned by Institutions (%) | 57.30% |
| Float | 95.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 269.74 |
| Forward PS | n/a |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.78, with a Debt / Equity ratio of 0.20.
| Current Ratio | 5.78 |
| Quick Ratio | 5.73 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -105.63% and return on invested capital (ROIC) is -58.24%.
| Return on Equity (ROE) | -105.63% |
| Return on Assets (ROA) | -51.79% |
| Return on Invested Capital (ROIC) | -58.24% |
| Return on Capital Employed (ROCE) | -107.85% |
| Weighted Average Cost of Capital (WACC) | 6.44% |
| Revenue Per Employee | $3,167 |
| Profits Per Employee | -$1.17M |
| Employee Count | 60 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.86% in the last 52 weeks. The beta is 0.66, so aTyr Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -84.86% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 39.29 |
| Average Volume (20 Days) | 3,621,424 |
Short Selling Information
The latest short interest is 19.85 million, so 20.24% of the outstanding shares have been sold short.
| Short Interest | 19.85M |
| Short Previous Month | 19.88M |
| Short % of Shares Out | 20.24% |
| Short % of Float | 20.76% |
| Short Ratio (days to cover) | 21.96 |
Income Statement
In the last 12 months, aTyr Pharma had revenue of $190,000 and -$70.03 million in losses. Loss per share was -$0.73.
| Revenue | 190,000 |
| Gross Profit | -55.53M |
| Operating Income | -73.29M |
| Pretax Income | -70.03M |
| Net Income | -70.03M |
| EBITDA | -72.63M |
| EBIT | -73.29M |
| Loss Per Share | -$0.73 |
Full Income StatementBalance Sheet
The company has $66.51 million in cash and $11.70 million in debt, with a net cash position of $54.81 million or $0.56 per share.
| Cash & Cash Equivalents | 66.51M |
| Total Debt | 11.70M |
| Net Cash | 54.81M |
| Net Cash Per Share | $0.56 |
| Equity (Book Value) | 57.74M |
| Book Value Per Share | 0.59 |
| Working Capital | 55.88M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$59.08 million and capital expenditures -$215,000, giving a free cash flow of -$59.30 million.
| Operating Cash Flow | -59.08M |
| Capital Expenditures | -215,000 |
| Depreciation & Amortization | 659,000 |
| Net Borrowing | -550,000 |
| Free Cash Flow | -59.30M |
| FCF Per Share | -$0.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -38,573.68% |
| Pretax Margin | -36,860.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.81% |
| Shareholder Yield | -20.81% |
| Earnings Yield | -136.64% |
| FCF Yield | -115.70% |
Analyst Forecast
The average price target for aTyr Pharma is $2.86, which is 464.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.86 |
| Price Target Difference | 464.33% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 185.95% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
aTyr Pharma has an Altman Z-Score of -6.6 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.6 |
| Piotroski F-Score | 1 |
